These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15155188)

  • 21. Iron influences the expression of Helicobacter pylori outer membrane vesicle-associated virulence factors.
    Keenan JI; Allardyce RA
    Eur J Gastroenterol Hepatol; 2000 Dec; 12(12):1267-73. PubMed ID: 11192314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of soluble haemagglutinins on adherence of Helicobacter pylori to HEp-2 cells.
    Armstrong JA; Cooper M; Goodwin CS; Robinson J; Wee SH; Burton M; Burke V
    J Med Microbiol; 1991 Mar; 34(3):181-7. PubMed ID: 2010909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of iron in Helicobacter pylori: its influence in outer membrane protein expression and in pathogenicity.
    Pérez-Pérez GI; Israel DA
    Eur J Gastroenterol Hepatol; 2000 Dec; 12(12):1263-5. PubMed ID: 11192313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
    Vogt K; Hahn H
    Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on the mechanism of action of colloidal bismuth subcitrate. I. Interaction with sulfhydryls.
    Beil W; Bierbaum S; Sewing KF
    Pharmacology; 1993 Aug; 47(2):135-40. PubMed ID: 8395060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of bismuth antibacterial activity with lipophilic thiol chelators.
    Domenico P; Salo RJ; Novick SG; Schoch PE; Van Horn K; Cunha BA
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1697-703. PubMed ID: 9257744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pterocarpus santalinus: an In Vitro study on its anti-Helicobacter pylori effect.
    Narayan S; Veeraraghavan M; Devi CS
    Phytother Res; 2007 Feb; 21(2):190-3. PubMed ID: 17128431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional disruption of peroxiredoxin by bismuth antiulcer drugs attenuates Helicobacter pylori survival.
    Chang YY; Cheng T; Yang X; Jin L; Sun H; Li H
    J Biol Inorg Chem; 2017 Jul; 22(5):673-683. PubMed ID: 28361362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation, characterization, and anti-Helicobacter pylori activity of Bi3+-Hericium erinaceus polysaccharide complex.
    Zhu Y; Chen Y; Li Q; Zhao T; Zhang M; Feng W; Takase M; Wu X; Zhou Z; Yang L; Wu X
    Carbohydr Polym; 2014 Sep; 110():231-7. PubMed ID: 24906751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study.
    Forné M; Viver JM; Espinós JC; Coll I; Tresserra F; Garau J
    Am J Gastroenterol; 1995 May; 90(5):718-21. PubMed ID: 7733075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of clarithromycin against intracellular Helicobacter pylori.
    Piccolomini R; Di Bonaventura G; Picciani C; Laterza F; Vecchiet J; Neri M
    Antimicrob Agents Chemother; 2001 May; 45(5):1568-71. PubMed ID: 11302831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and characterisation of bismuth(III) aminoarenesulfonate complexes and their powerful bactericidal activity against Helicobacter pylori.
    Busse M; Trinh I; Junk PC; Ferrero RL; Andrews PC
    Chemistry; 2013 Apr; 19(17):5264-75. PubMed ID: 23536213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological therapy of Helicobacter pylori infection.
    Hoffman JS
    Semin Gastrointest Dis; 1997 Jul; 8(3):156-63. PubMed ID: 9232728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in Helicobacter pylori outer membrane and outer membrane vesicle-associated lipopolysaccharides under iron-limiting growth conditions.
    Keenan JI; Davis KA; Beaugie CR; McGovern JJ; Moran AP
    Innate Immun; 2008 Oct; 14(5):279-90. PubMed ID: 18809652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The actions of bismuth in the treatment of Helicobacter pylori infections: an update.
    Ge R; Chen Z; Zhou Q
    Metallomics; 2012 Mar; 4(3):239-43. PubMed ID: 22358069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mono and dual therapy for Helicobacter pylori associated gastritis.
    Gill HH; Desai HG; Mehta PR; Ranganathan S; Kalro RH; Murti PK; Prabhu SR
    J Assoc Physicians India; 1991 Oct; 39(10):743-5. PubMed ID: 1816196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of fumarase by bismuth(III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori.
    Chen Z; Zhou Q; Ge R
    Biometals; 2012 Feb; 25(1):95-102. PubMed ID: 21818585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to bismuth among gram-negative bacteria is dependent upon iron and its uptake.
    Domenico P; Reich J; Madonia W; Cunha BA
    J Antimicrob Chemother; 1996 Dec; 38(6):1031-40. PubMed ID: 9023650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of NikR from Helicobacter pylori by a bismuth drug.
    Guo Y; Guan C; Wan H; Zhang Z; Li H; Sun H; Xia W
    J Inorg Biochem; 2019 Jul; 196():110685. PubMed ID: 30999221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.